Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	10/531,726
Filing Date	October 20, 2003
First Named Inventor	Anke Klippel-Giese
Art Unit	1635
Examiner Name	Richard A. Schnizer., Ph.D.
Attorney Docket Number	ST.103T

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number - Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3] - Number[4] - Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	F1	WO 00/44895	08-03-2000	Kreutzer *et al.*	All	
	F2	WO 01/75164	10-11-2001	Whitehead Institute for Biomedical Research	All	
	F3	AU 778474	12-09-2004	Kreutzer *et al.*	All	
	F4					
	F5					
	F6					
	F7					

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2	of	2

	Complete if Known
Application Number	10/531,726
Filing Date	October 20, 2003
First Named Inventor	Anke Klippel-Giese
Group Art Unit	1635
Examiner Name	Richard A. Schnizer., Ph.D.
Attorney Docket Number	ST.103T

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	R1	WATERS, J. S. *et al.* "Phase I Clinical and Pharmacokinetic Study of Bel-2 Antisense Oligonucleotide Therapy in Patients with Non-Hodgkin's Lymphoma" *J. Clin. Oncol.*, May 2000, pp. 1812-1823, Vol. 18, No. 9.	
	R2	CHI, K. N. *et al.* "A Phase I Dose-finding Study of Combined Treatment with an Antisense Bcl-2 Oligonucleotide (Genasense) and Mitoxantrone in Patients with Metastatic Hormone-refractory Prostate Cancer" *Clinical Cancer Research*, December 2001, pp. 3920-3927, Vol. 7.	
	R3	NEMUNAITIS, J. *et al.* "Phase I Evaluation of ISIS 3521, an Antisense Oligodeoxynucleotide to Protein Kinase C-Alpha, in Patients with Advanced Cancer" *Journal of Clinical Oncology*, November 1999, pp. 3586-3595, Vol. 17, No. 11.	
	R4	CUNNINGHAM, C. *et al.* "A Phase I Trial of H-*ras* Antisense Oligonucleotide ISIS 2503 Administered as a Continuous Intravenous Infusion in Patients with Advanced Carcinoma" *Cancer*, 2001, pp. 1265-1271, Vol. 92.	
	R5	OGRIS, M. *et al.* "Targeting tumors with non-viral gene delivery systems" *Drug Discovery Today*, April 2002, pp. 479-485, Vol. 7, No. 8.	
	R6	CUNNINGHAM, C. *et al.* " A Phase I Trial of c-*Raf* Kinase Antisense Oligonucleotide ISIS 5132 Administered as a Continuous Intravenous Infusion in Patients with Advanced Cancer" *Clinical Cancer Research*, May 2000, pp. 1626-1631, Vol. 6.	
	R7	YUEN, A. R. *et al.* "Phase I Study of an Antisense Oligonucleotide to Protein Kinase C-α (ISIS 3521/CGP 64128A) in Patients with Cancer" *Clinical Cancer Research*, November 1999, pp. 3357-3363, Vol. 5.	
	R8	DEVROE, E. *et al.* "Retrovirus-delivered siRNA" *BMC Biotechnology*, 2002, pp. 1-5, Vol. 2.	
	R9	YACYSHYN, B.R. *et al.* "A Placebo-Controlled Trial of ICAM-1 Antisense Oligonucleotide in the Treatment of Crohn's Disease" *Gastroenterology*, 1998, pp. 1133-1142, Vol. 114.	
	R10	JENSEN, B. *et al.* "Chemosensitisation of malignant melanoma by BCL2 antisense therapy" *The Lancet*, November 18, 2000, pp. 1728-1733, Vol. 326.	
	R11		
	R12		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.